Companies › MabQuest
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jun 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MAQ-001 Anti-PD-1 monoclonal antibody with alternative mechanism independent of PD-1/PD-L1 blockad | PDCD1 | Phase 1 | Advanced Solid Tumor | Jun 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06514651 | MAQ-001 | Phase 1 | Advanced Solid Tumor | Oncology | Jun 2028 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.